Bitwise Acquires Chorus One to Boost Multi‑Chain Staking, Including SOL

Bitwise has acquired staking provider Chorus One, bringing over $2.2 billion in staked assets and roughly 50 employees into Bitwise Onchain Solutions. The undisclosed deal expands Bitwise’s institutional staking infrastructure across more than 30 proof‑of‑stake chains — notably Solana (SOL), Sui, Aptos, Avalanche (AVAX), Tezos (XTZ) and Monad — and transfers Chorus One CEO Brian Crain to an advisory role. Bitwise (managing ~ $15 billion across 40+ products) says the move strengthens its staking capabilities for institutions and retail clients and could support growth in staking-related ETFs such as the Bitwise Solana Staking ETF (BSOL). Analysts cited in later coverage noted the acquisition may make staking rewards more accessible and bolster long‑term SOL fundamentals; however, short‑term technicals for SOL remain weak (oversold RSI and ongoing downtrend). The deal size was not disclosed. Primary keywords: Bitwise, Chorus One, staking, staked ETFs, Solana, multi‑chain staking.
Bullish
The acquisition is likely bullish for SOL over the medium to long term because it increases institutional-grade staking capacity and distribution channels for staking rewards. By integrating Chorus One’s $2.2B in staked assets and infrastructure, Bitwise can scale staking services (including through ETFs like BSOL), lowering operational frictions for institutional and retail participation. Greater on‑chain staking demand and easier access to staking rewards historically support token fundamentals (reduced circulating supply, steady lockups, and increased demand from custodians/funds). However, the near‑term price impact may be muted or mixed: later reporting notes SOL technicals are oversold and in a downtrend, so traders could see limited upside until market sentiment and momentum improve. In short: strategic and structural positives for SOL’s fundamentals (bullish medium/long term), but short‑term price action may remain constrained by existing bearish technicals.